Canlyniadau Chwilio - Richárd Márkus

  • Dangos 1 - 7 canlyniadau o 7
Mireinio'r Canlyniadau
  1. 1
    A randomized, single-blind, single-dose study evaluating the pharmacokinetic equivalence of proposed biosimilar ABP 980 and trastuzumab in healthy male subjects

    A randomized, single-blind, single-dose study evaluating the pharmacokinetic equivalence of proposed biosimilar ABP 980 and trastuzumab in healthy male subjects gan Vladimir Hanes, Vincent Chow, Nan Zhang, Richárd Márkus

    Cyhoeddwyd 2017
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  2. 2
    A randomised, single-blind, single-dose, three-arm, parallel-group study in healthy subjects to demonstrate pharmacokinetic equivalence of ABP 501 and adalimumab

    A randomised, single-blind, single-dose, three-arm, parallel-group study in healthy subjects to demonstrate pharmacokinetic equivalence of ABP 501 and adalimumab gan Primal Kaur, Vincent Chow, Nan Zhang, Michael Moxness, Arunan Kaliyaperumal, Richárd Márkus

    Cyhoeddwyd 2016
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  3. 3
    Developing the Totality of Evidence for Biosimilars: Regulatory Considerations and Building Confidence for the Healthcare Community

    Developing the Totality of Evidence for Biosimilars: Regulatory Considerations and Building Confidence for the Healthcare Community gan Richárd Márkus, Jennifer Liu, Monica Ramchandani, Diana Landa, Teresa L. Born, Primal Kaur

    Cyhoeddwyd 2017
    Cael y testun llawn Cael y testun llawn
    Revisão
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  4. 4
    Estimation of Cachexia among Cancer Patients Based on Four Definitions

    Estimation of Cachexia among Cancer Patients Based on Four Definitions gan Kathleen M. Fox, John M. Brooks, Shravanthi R. Gandra, Richárd Márkus, Chiun‐Fang Chiou

    Cyhoeddwyd 2009
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  5. 5
    Intralymphatic allergen administration renders specific immunotherapy faster and safer: A randomized controlled trial

    Intralymphatic allergen administration renders specific immunotherapy faster and safer: A randomized controlled trial gan Gabriela Senti, Bettina M. Prinz Vavricka, Iris Erdmann, Mella I. Diaz, Richárd Márkus, Stephen J. McCormack, John Simard, Brunello Wüthrich, Reto Crameri, Nicole Graf, Pål Johansen, Thomas M. Kündig

    Cyhoeddwyd 2008
    Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  6. 6
    Microbiology, safety, and pharmacokinetics of aztreonam lysinate for inhalation in patients with cystic fibrosis

    Microbiology, safety, and pharmacokinetics of aztreonam lysinate for inhalation in patients with cystic fibrosis gan Ronald L. Gibson, George Retsch‐Bogart, Christopher M. Oermann, Carlos Milla, Joseph M. Pilewski, Cori Daines, Richard C. Ahrens, Kevin León, Morty Cohen, Sharon McNamara, Tracy L. Callahan, Richárd Márkus, Jane L. Burns

    Cyhoeddwyd 2006
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  7. 7
    NCCN Biosimilars White Paper: Regulatory, Scientific, and Patient Safety Perspectives

    NCCN Biosimilars White Paper: Regulatory, Scientific, and Patient Safety Perspectives gan Andrew D. Zelenetz, Islah Ahmed, Edward L. Braud, James D. Cross, Nancy Davenport-Ennis, Barry D. Dickinson, Steven E. Goldberg, Scott Gottlieb, Philip E. Johnson, Gary H. Lyman, Richárd Márkus, Ursula A. Matulonis, Denise K. Reinke, Edward C. Li, Jessica K. DeMartino, Jonathan K. Larsen, James M. Hoffman

    Cyhoeddwyd 2011
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:

Offerynnau Chwilio: